114 Systemic Treatment Decision Making for Patients with Stage I and II, Hormone Receptor Positive, Her2/neu Negative Breast CancerBackground: Oncotype DX is a clinically validated risk stratification tool that can predict the risk of recurrence and the benefit of adjuvant chemotherapy in women with...
Chaudhary LN, Jorns JM, Sun Y, et al. Frequent upregulation of HER2 protein in hormone-receptor-positive HER2-negative breast cancer after short-term neoadjuvant endocrine therapy. Breast Cancer Res Treat. 2023;201(...
REVIEW Bevacizumab in the treatment of HER2-negative breast cancer Vito Lorusso Oncologic Institute,Vito Fazzi Hospital, Lecce, Italy Correspondence: Vito Lorusso P.zza Muratore, 1-73100 Lecce, Italy Tel/Fax +39 0832 661962 Email vitolorusso@inwind.it Abstract: Angiogenesis has a clear and ...
目前还有不少药物正在进一步探索该人群的疗效,包括ADC药物(DS8201、SYD985、ARX788、A166、PF-06804103、FS-1502及XMT-1522);单克隆抗体(Margetuximab);疫苗(HER-2/neu peptide、AdHER2/neu DC vaccine);双特异性抗体(MCLA-128、ZW25、BTRC401...
[3]Slamon DJ,et al.Human breast cancer:correlation of relapse and survival with amplifcation of the HER-2/neuoncogene.Science 1987;235:177–82. [4]Eiger D,et al.The Exciting New Field of HER2-Low Breast Cancer Treatment.Cancers 2021;13:1015. ...
HER2/neu in systemic therapy for women with breast cancer: a systematic review. Breast Cancer Res Treat 2008;109:209-29.↵ Dhesy-Thind B , Pritchard KI , Messersmith H , et al . HER2/neu in systemic therapy for women with breast cancer: a systematic review . Breast Cancer Res Treat ...
12.Garrido C,et al.Analytical and clinical validation of PATHWAY Anti-HER-2/neu(4B5)antibody to assess HER2-low status for trastuzumab deruxtecan treatment in breast cancer.Virchows Arch.2023 Oct 20. 13.Ansh Kapil,et al.HER2 quantitative continuous scoring for accurate patient selection in HER...
The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target was a major breakthrough for the treatment of highly aggressive HER2-positive breast cancer, leading to approval of the first HER2-targeted drug — the monoclonal
Currently, the human epidermal growth factor receptor 2 (HER2) status of breast cancer is classified dichotomously as negative or positive to select patients for HER2-targeted therapy. However, with the introduction of novel treatment options, it is important to get more insight in the biology of...
Abnormal alterations in human epidermal growth factor receptor 2 (HER2, neu, and erbB2) are associated with the development of many tumors. It is currently a crucial treatment for multiple cancers. Advanced in molecular biology and further exploration of the HER2-mediated pathway have promoted the...